Login to Your Account



Intercept ‘POISE’d for PBC filings as SAEs distract investors

By Jennifer Boggs
Managing Editor

Monday, March 17, 2014

Positive phase III data for Intercept Pharmaceuticals Inc.’s obeticholic acid in primary biliary cirrhosis and plans for regulatory submissions in both the U.S. and Europe were overshadowed Monday as the market reacted to reports of two serious adverse events from a midstage study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription